Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
NCT05145400
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study wants to see if a mix of three drugs (isatuximab, lenalidomide, and dexamethasone) is safe and works well to treat a certain kind of cancer called multiple myeloma. They will use lower doses of the drugs to try and avoid bad side effects. This way of using the drugs has not been officially approved by the FDA yet.
This study wants to see if a mix of three drugs (isatuximab, lenalidomide, and dexamethasone) is safe and works well to treat a certain kind of cancer called multiple myeloma. They will use lower doses of the drugs to try and avoid bad side effects. This way of using the drugs has not been officially approved by the FDA yet.
Third Opinion AI Generated Synopsis
Trial Summary
This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide and dexamethasone, has not been approved by the Food and Drug Administration (FDA) for the treatment of newly diagnosed MM.
This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide and dexamethasone, has not been approved by the Food and Drug Administration (FDA) for the treatment of newly diagnosed MM.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
